Form 4: Jazz Pharma Director's Tax-Related Share Disposition

Jazz Pharmaceuticals director Bruce C. Cozadd disposed of 15,647 ordinary shares to cover tax obligations related to restricted stock unit vesting.

Summary

• Bruce C. Cozadd, a Director of Jazz Pharmaceuticals plc, reported a transaction on September 14, 2025.
• The transaction involved the disposition of 15,647 ordinary shares.
• These shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• The deemed price per share for tax purposes was $126.16.
• Following this transaction, Bruce C. Cozadd beneficially owns 414,326 ordinary shares directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary insider transaction for tax purposes, which is neutral in sentiment.

Negatives

• Direct beneficial ownership of ordinary shares by Bruce C. Cozadd decreased by 15,647 shares.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction related to executive compensation and tax obligations, which is common across all industries for publicly traded companies with equity compensation plans. It does not provide specific insights into broader industry trends for the pharmaceutical sector.

Stakeholder Impact

• Shareholders: A minor, routine reduction in a director's direct ownership, which is a common occurrence with equity compensation vesting and tax withholding. No material impact on overall shareholder value or company operations is implied.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by a director to cover tax obligations arising from restricted stock unit vesting. Such transactions are common and do not reflect a change in the director's confidence in the company or its future prospects. The filing provides no new fundamental information about Jazz Pharmaceuticals' financial health, strategic direction, or operational performance that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the core investment thesis remains unchanged based on this specific filing.

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Transaction, Share Disposition, Restricted Stock Units, RSU, Tax Withholding, Director